Leading translational and clinical researchers to share new insights and best practices using Imaging Mass Cytometry
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced it will hold its 2nd Annual Imaging Mass Cytometry User Group Meeting September 10–11 at the Seattle Art Museum. In this exciting program preceding the World Molecular Imaging Congress, leading academic and pharmaceutical researchers will share new insights in health and disease uncovered with the use of Imaging Mass Cytometry™ (IMC). Best practices and new advances in multiplexed data analysis utilizing a range of third-party software will also be discussed, emphasizing an exciting area of continuous improvement and innovation.
“The Hyperion™ Imaging System is having a palpable impact on translational and clinical research programs around the world,” said Chris Linthwaite, President and CEO of Fluidigm. “We see tremendous potential ahead as the growing IMC™ community unlocks the full power of this transformational imaging technology.”
Bernd Bodenmiller, a key innovator in IMC applications from the University of Zurich will offer the keynote presentation at the start of the meeting. In his presentation, he will share his recent work using IMC to understand the mechanisms of type 1 diabetes. He will also share his research investigating the underpinnings of cancer using 3D modeling, a new IMC method recently developed in his group.
“The progress made by the IMC community over the past year has been profound and impressive,” said Bodenmiller. “By providing a comprehensive view into complex tissue and tumor microenvironments at subcellular resolution, IMC is aiding in the identification of potential new biomarkers and cellular social networks that correlate with disease progression and therapeutic response, including defining interactions with the immune system.”
“We are excited to host this upcoming user group meeting for the IMC community. The meeting will highlight scientific breakthroughs, facilitate dissemination of best practices, stimulate new collaborations and inspire new investigations,” said Linthwaite. “Together with the user community, we see IMC as a powerful tool to reveal new insights in health and disease today with the potential to improve lives in the future.”
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, Hyperion, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.
Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the benefits and uses of the Hyperion Imaging System and outcomes of the user group meeting. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to uncertainties in contractual relationships and international regulated markets; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation